INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.

Ultragenyx's Phase 3 Aspire trial of apazunersen (GTX-102) in Angelman syndrome failed both its primary cognitive endpoint and key secondary MDRI response endpoint. Shares fell $11.68, or 44.03%, to $14.85 on September 3, 2026. Pomerantz LLP is investigating potential securities-fraud and other unlawful-business-practice claims related to the company and its officers or directors.

Analysis

The legal notice itself is not incremental to RARE’s fundamental value; the relevant issue is whether the pipeline reset forces a lower probability-weighted revenue base while fixed R&D and commercial infrastructure remain sized for a broader rare-disease portfolio. With the shares already repriced sharply, follow-on litigation expense should be immaterial versus the potential need to fund development, but discovery could expose prior efficacy expectations or disclosure practices and prolong the valuation overhang. In biotech, that overhang typically suppresses strategic-buyer interest and raises the cost of any equity financing for 6-12 months.

Near term, the key question is cash runway after removing the failed program’s expected value and any associated development spend. A credible discontinuation/reallocation plan, cash runway extending beyond the next major readout, and reaffirmed guidance for marketed assets could support a technical rebound over 1-3 months; absent those, the stock is vulnerable to further dilution-driven downside. Watch management’s updated operating-expense trajectory, net product revenue growth, and any change in cash-use guidance rather than lawsuit headlines.

Consensus may overstate the read-through to Ultragenyx’s entire platform: a failed CNS endpoint does not mechanically impair commercial rare-disease franchises or programs with distinct biology. However, the opposite risk is that investors had assigned the asset more than a modest probability-adjusted contribution, making a seemingly large one-day move insufficient if revised sum-of-the-parts work reveals a cash value floor materially below the current enterprise value. There is no clean public-company beneficiary; the more relevant second-order effect is reduced competitive pressure for other Angelman-focused developers, though the addressable market remains too small to justify a broad sector trade.

Key Decisions for Investors

• Do not initiate a directional position solely on the plaintiff-firm announcement; treat it as a liquidity/volatility alert, not a new fundamental catalyst.
• Maintain or establish a tactical RARE short only on failed rebounds into the next earnings or investor-update window if management does not provide a quantified opex reset and runway beyond 12 months; target 15-25% downside from the rebound level, with a stop on cash guidance improvement or durable revenue outperformance.
• For existing RARE longs, reduce gross exposure until updated cash burn, product-revenue guidance, and pipeline prioritization are disclosed. Re-enter only if the post-reset enterprise value is supported by commercial-asset cash flows and management demonstrates no near-term equity-financing requirement.
• Monitor SEC filings and conference-call language for evidence of prior internal efficacy concerns, changes to trial disclosure, or reserve accruals. Those would increase governance risk and justify maintaining a discount to rare-disease biotech peers for 6-18 months.